TORONTO & SAN DIEGO--(BUSINESS WIRE)--Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced an expansion of its strategic collaboration with Celgene Corporation. The supplemental agreement adds a Phase I development program that will explore combining an intravenous (IV) formulation of marizomib with bevacizumab in glioblastoma (GBM), an aggressive malignant primary brain tumor.
“We have made important progress in our existing collaboration with Celgene and are now expanding the collaboration with the addition of a new clinical study in a very high unmet medical need setting,” said Frank Stonebanks, founder, president and CEO of Triphase. “This supplemental agreement with Celgene provides us with the resources to study the novel proteasome inhibitor marizomib and explore its potential to make a meaningful difference in the treatment of GBM.”
Help employers find you! Check out all the jobs and post your resume.
“We have made important progress in our existing collaboration with Celgene and are now expanding the collaboration with the addition of a new clinical study in a very high unmet medical need setting,” said Frank Stonebanks, founder, president and CEO of Triphase. “This supplemental agreement with Celgene provides us with the resources to study the novel proteasome inhibitor marizomib and explore its potential to make a meaningful difference in the treatment of GBM.”
Help employers find you! Check out all the jobs and post your resume.
